Bora Pharmaceuticals (BORA.Y) Stock Overview

Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. More details

BORA.Y fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	6/6
Past Performance	2/6
Financial Health	5/6
Dividends	4/6

Rewards

Trading at 81.5% below our estimate of its fair value

Earnings are forecast to grow 25.76% per year

Earnings have grown 39.9% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Unstable dividend track record

Large one-off items impacting financial results

Has a high level of debt

BORA.Y Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.

View narrative

stuart_roberts

Community Contributor

US$21.53FV • 69.3% undervalued

5419.8%Revenue growth p.a.

5.5k

110

2mo ago

Bora Pharmaceuticals Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bora Pharmaceuticals
Historical stock prices
Current Share Price	NT$3.20
52 Week High	NT$5.00
52 Week Low	NT$3.17
Beta	0.79
1 Month Change	-6.43%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-28.89%

Recent updates

Shareholder Returns

	BORA.Y	US Pharmaceuticals	US Market
7D	0%	2.4%	4.4%
1Y	n/a	38.2%	31.9%

Return vs Industry: Insufficient data to determine how BORA.Y performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BORA.Y performed against the US Market.

Price Volatility

Is BORA.Y's price volatile compared to industry and market?
BORA.Y volatility
BORA.Y Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	7.1%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.3%

Stable Share Price: BORA.Y's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BORA.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	n/a	Bobby Sheng	www.bora-corp.com

Bora Pharmaceuticals Co., Ltd. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs.

Bora Pharmaceuticals Co., Ltd. Fundamentals Summary

How do Bora Pharmaceuticals's earnings and revenue compare to its market cap?
BORA.Y fundamental statistics
Market cap	US$1.78b
Earnings (TTM)	US$137.16m
Revenue (TTM)	US$594.97m

13.0x

P/E Ratio

3.0x

P/S Ratio

Is BORA.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BORA.Y income statement (TTM)
Revenue	NT$19.01b
Cost of Revenue	NT$11.16b
Gross Profit	NT$7.85b
Other Expenses	NT$3.47b
Earnings	NT$4.38b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	34.52
Gross Margin	41.30%
Net Profit Margin	23.05%
Debt/Equity Ratio	99.8%

How did BORA.Y perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

28%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/07 04:02
End of Day Share Price	2026/03/24 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bora Pharmaceuticals Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jianzheng Wu	Capital Securities Corporation
Chenghsin Lin	J.P. Morgan
null null	KGI Securities Co. Ltd.

Bora Pharmaceuticals Co., Ltd.OTCPK:BORA.Y Stock Report